Christian Hartinger

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Christian Hartinger
Christian Hartinger
Christian Hartinger
Vienna, Austria
ResidenceAuckland, New Zealand
Alma materUniversity of Vienna (MSc, 1999; PhD, 2001; Habilitation, 2009)
Known for
AwardsNew Zealand Institute of Chemistry Maurice Wilkins Centre Prize
Scientific career
InstitutionsThe University of Auckland
Doctoral advisorBernhard Keppler

Christian G. Hartinger (born 1974) is an Austrian-born New Zealand bioinorganic chemist known for his work in metal-based anticancer drugs.

Scientific career[edit]

Hartinger studied chemistry at the University of Vienna, earning his MSc in 1999 and his PhD in 2001 under Bernhard Keppler. He was an Erwin Schrödinger Fellow with Paul Dyson at the École Polytechnique Fédérale de Lausanne from 2006 to 2008 and obtained his habilitation at the University of Vienna in 2009. In 2011, Hartinger was appointed the position of Associate Professor at The University of Auckland, where he currently serves and in 2015 was promoted to professor. He was also made deputy Head of School of Chemical Sciences in 2013.

Hartinger's research interests are in bioinorganic chemistry, medicinal chemistry, and bioanalytical chemistry, where he uses an interdisciplinary approach in drug discovery. He is specially interested in the development of metal-centred anticancer agents, particularly ruthenium anticancer drugs, and using analytical methods to characterise their behaviour in the presence of biomolecules.[1]

Hartinger has now published over 168 publications and has an h-index of 50.[2]


Year Distinction/honour Organisation
2005 Theodor Körner Prize Theodor Körner Fund
2006 Erwin Schrödinger Fellowship Austrian Science Fund
2009 Best Paper Award for the publication Modifying the Structure of Dinuclear Ruthenium Complexes with Antitumor Activity[3] Applied Organometallic Chemistry
2010 Innovative Teaching Award Bank Austria
Visiting Professor Chimie ParisTech, France
2011 Carl Duisberg Memorial Prize German Chemical Society
2013 Visiting Professor University of Vienna
2014 Scientific Organizing Committee Co-chair 7th International Symposium on Bioorganometallic Chemistry
2016 Chair of the 8th Asian Biological Inorganic Chemistry Conference 8th Asian Biological Inorganic Chemistry (AsBIC) Conference
2016 SBIC Early Career Award 2016 Society of Biological Inorganic Chemistry
2016 New Zealand Institute of Chemistry Maurice Wilkins Centre Prize Maurice Wilkins Centre
2017 Hood Fellowship (Cambridge, UK) The University of Auckland Foundation

Selected research outputs[edit]

  • Meier, S. M.; Novak, M. S.; Kandioller, W.; Jakupec, M. A.; Roller, A.; Keppler, B. K.; Hartinger, C. G., Aqueous chemistry and antiproliferative activity of a pyrone-based phosphoramidate Ru(arene) anticancer agent. Dalton Trans, 2014, 43 (26), 9851–9855
  • Meier, S. M.; Babak, M. V.; Keppler, B. K.; Hartinger, C. G., Efficiently detecting metallodrug-protein adducts: ion trap versus time-of-flight mass analyzers. ChemMedChem, 2014, 9 (7), 1351–1355
  • Hartinger, C. G.; Groessl, M.; Meier, S. M.; Casini, A.; Dyson, P. J., Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs. Chem Soc Rev, 2013, 42 (14), 6186–6199
  • Meier, S. M.; Novak, M.; Kandioller, W.; Jakupec, M. A.; Arion, V. B.; Metzler-Nolte, N.; Keppler, B. K.; Hartinger, C. G., Identification of the structural determinants for anticancer activity of a ruthenium arene peptide conjugate. Chem Eur J, 2013, 19 (28), 9297–9307
  • Kandioller, W.; Balsano, E.; Meier, S. M.; Jungwirth, U.; Göschl S.; Roller, A.; Jakupec, M. A.; Berger, W.; Keppler, B. K.; Hartinger, C. G., Organometallic anticancer complexes of lapachol: metal centre-dependent formation of reactive oxygen species and correlation with cytotoxicity. Chem Commun, 2013, 49 (32), 3348–3350
  • Meier, S. M.; Hanif, M.; Pichler, V.; Novak, M.; Jirkovsky, E.; Jakupec, M. A.; Davey, C. A.; Keppler, B. K.; Hartinger, C. G., Novel metal(II) arene 2-pyridinecarbothioamides: A rationale to orally active organometallic anticancer agents. Chem Sci, 2013, 4 (4), 1837–1846
  • Babak, M. V.; Meier, S. M.; Legin, A. A.; Adib Razavi, M. S.; Roller, A.; Jakupec, M. A.; Keppler, B. K.; Hartinger, C. G., Am(m)ines make the difference: organoruthenium am(m)ine complexes and their chemistry in anticancer drug development. Chemistry, 2013, 19 (13), 4308–4318
  • Kurzwernhart, A.; Kandioller, W.; Bächler S.; Bartel, C.; Martic, S.; Buczkowska, M.; Mühlgassner, G.; Jakupec, M. A.; Kraatz, H.; Berdnarski, P. J.; Arion, V .B.; Markos, D.; Keppler, B. K.; Hartinger, C. G., Structure-activity relationships of targeted RuII6-p-cymene) anticancer complexes with flavonol-derived ligands. J Med Chem, 2012, 55 (23), 10512-10522


  1. ^ Jakupec, M. A.; Galanski, M.; Arion, V. B.; Hartinger, C. G. & Keppler, B. K. (2008). "Antitumour metal compounds: more than theme and variations". Dalton Transactions (2): 183–194. doi:10.1039/b712656p.
  2. ^ "Christian Hartinger's Google Scholar profile". Retrieved 10 March 2017.
  3. ^ Mendoza-Ferri, M. G.; Hartinger, C. G.; Alexey, A. A.; Kandioller, W.; Severin, K. & Keppler, B. K. (2008). "Modifying the Structure of Dinuclear Ruthenium Complexes with Antitumor Activity". Applied Organometallic Chemistry. 22 (6): 326–332. doi:10.1002/aoc.1394.

External links[edit]